Despite two decades of intensified research to understand and cure tuberculosis disease,
biological uncertainties remain and hamper progress. However, owing to collaborative …

Over the past 2000 years, tuberculosis (TB) has claimed more lives than any other infectious
disease. In 2020 alone, TB was responsible for 1.5 million deaths worldwide, comparable to …

Tuberculosis (TB) remains a leading cause of infectious death worldwide, and poverty is a
major driver. Clinically, TB presents as “latent” TB and active TB disease, and the treatment …

Given the low treatment success rates of drug-resistant tuberculosis (TB), novel TB drugs are
urgently needed. The landscape of TB treatment has changed considerably over the last …

Tuberculous meningitis (TB meningitis) is the most severe form of tuberculosis (TB),
requiring 12 months of multidrug treatment for cure, and is associated with high morbidity …

Tuberculosis (TB) drug discovery and development has undergone nothing short of a
revolution over the past 20 years. Successful public–private partnerships and sustained …

Introduction Tuberculosis requires lengthy multi-drug therapy. Mycobacterium tuberculosis
occupies different tissue compartments during infection, making drug access and …

Novel regimens combining bedaquiline and pretomanid with either linezolid (BPaL regimen)
or moxifloxacin and pyrazinamide (BPaMZ regimen) shorten the treatment duration needed …

Lengthy multidrug chemotherapy is required to achieve a durable cure in tuberculosis.
However, we lack well-validated, high-throughput in vitro models that predict animal …

Abstract Three-dimensional (3D) human tissue models/microphysiological systems (eg,
organs-on-chips, organoids, and tissue explants) model HIV and related comorbidities and …